Jefferies cuts PT on BioAge after obesity drug trial halted

** Shares of drug developer BioAge Labs BBIOA down ~70% to $6.13 premarket

** Brokerage Jefferies downgrades stock to "hold" from "buy"; lowers PT to $7 from $42

** New PT represents a 65.2% downside to Friday's close of $20.09

** Brokerage lowers PT on discontinuation of co's mid-stage obesity drug trial due to liver safety concerns

** Brokerage expects significant "stock drop"

** Brokerage also lowers co's drug pipeline value to $200 mln from $300 mln

** As of last close, stock has fallen 10.7% YTD